NQO2 [SC06-68] Antibody

NAD (P) H:quinone oxidoreductase 1 (NQO1) and NRH:quinone oxidoreductase (NQO2) are flavoproteins that catalyze the metabolic detoxification of quinones and their derivatives to hydroquinones. This detoxification process protects cells against quinone-induced oxidative stress, cytotoxicity and mutagenicity. NQO2 is a 231 amino acid protein and is 43 amino acids shorter than NQO1 at its C-terminus. NQO2 is an isozyme of NQO1 and transfers two electrons to a quinone, resulting in the formation of a hydroquinone product . The NQO2 gene is ubiquitously expressed and induced in response to TCDD. NQO2 has a higher level of expression in mouse liver and testis than NQO1, which is highly expressed in the heart. NQO2 has a different cofactor requirement than NQO1 and uses dihydronicotinamide riboside (NRH) rather than NAD (P) H as an electron donor. Unlike NQO1, NQO2 is resistant to typical inhibitors of NQO1 such as dicoumarol, Cibacron blue and phenindonee, but is inhibited by quercetin and benzo (a) pyrene. NQO2 contains a specific metal binding site, which is absent in NQO1 and several cis-elements including SP1 binding sites, CCAAT box, XRE and ARE, which are located at the NQO2 gene promoter.